Clinical Trials Logo

Metabolic Syndrome X clinical trials

View clinical trials related to Metabolic Syndrome X.

Filter by:

NCT ID: NCT00916175 Completed - Metabolic Syndrome Clinical Trials

Metabolic Syndrome and Functional Food

Start date: October 2008
Phase: Phase 2/Phase 3
Study type: Interventional

High blood sugar and adiposity are part of Metabolic syndrome (about 24% of adults harbor it). The main approach, weight reduction, is often unattainable. Aloe Vera (barbadensis) (AV) and cnidoscolus chayamansa (McVaugh)(CC) are two vegetables that seem to have an effect on blood glucose and body weight. The study aims to determine if the intake of aloe gel and/or Chaya infusion can reduce high blood sugar in adult women with pre-diabetes (Metabolic Syndrome). Methods: A Factorial assay, double blind, cross-over-controlled with random assignment, to four treatments: AV and CC, AV and Placebo 1, Placebo 2 and CC, and Placebo 1 and Placebo 2, at the outpatient clinic of the university Hospital and a community clinic. Two treatment periods of 4 weeks intermediated by one week for wash-out.

NCT ID: NCT00914251 Recruiting - Metabolic Syndrome Clinical Trials

Vascular Effects of Hesperidin in Metabolic Syndrome

Start date: November 2008
Phase: Phase 2
Study type: Interventional

It has been suggested that cardiovascular risk factors either independently or in cluster (metabolic syndrome) increase the risk of both type 2 diabetes (DM2) and cardiovascular diseases (CVD). Consumption of citrus fruits is linked to reduced cardiovascular morbidity and mortality. Hesperidin is a flavanone abundant in citrus fruit with putative vasodilator actions in vitro. While molecular mechanisms of vascular actions of hesperidin begin to be explored, no data on in vivo vascular effect of this flavanone has been ever acquired.

NCT ID: NCT00912210 Completed - Obesity Clinical Trials

Higher Protein Diet and Exercise for Optimal Weight Loss in Elderly Women

Start date: April 2009
Phase: Phase 1
Study type: Interventional

The broad aim is to determine efficacy of a weight loss diet higher in protein and lower in carbohydrate combined with low intensity exercise to favorably impact body composition, bone health, physical function, metabolic disease and quality of life compared to a conventional higher carbohydrate diet in overweight women over age 60.

NCT ID: NCT00911885 Completed - Metabolic Syndrome Clinical Trials

A Simple Dietary Message to Improve Dietary Quality for Metabolic Syndrome

CANDO
Start date: April 2009
Phase: N/A
Study type: Interventional

Identifying a simple dietary recommendation for weight loss and metabolic health may demonstrate potential for a simple public health message to impact coronary heart disease (CHD) prevention and metabolic syndrome. In a randomized clinical trial, the investigators propose to compare the efficacy of two intervention approaches to dietary change for CHD prevention among persons with metabolic syndrome. The two approaches are 1) the AHA Dietary Guidelines; and 2) a simple dietary change condition that focuses on increasing fiber. The investigators hypothesize that a message promoting high fiber intake may be the simple message that has potential to produce broad impact.

NCT ID: NCT00907127 Completed - Metabolic Syndrome Clinical Trials

Cardiac Autonomic Neuropathy in Patients With Metabolic Syndrome

CAN
Start date: January 2007
Phase: Phase 1
Study type: Interventional

The study will test whether damage of the heart nerves appears in patients before they develop diabetes.

NCT ID: NCT00891267 Completed - Hypertension Clinical Trials

Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome

VAMOS
Start date: October 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to study the effect of two doses of olmesartan medoxomil and amlodipine on vascular markers in hypertensive patients with metabolic syndrome.

NCT ID: NCT00885313 Completed - Obesity Clinical Trials

Effects of Docosahexaenoic Acid (DHA) on Children With Nonalcoholic Fatty Liver Disease (NAFLD)

EDACN
Start date: March 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this interventional study is to evaluate the efficacy and tolerability of docosahexaenoic acid (DHA) in children or adolescents with well-characterized and liver biopsy confirmed nonalcoholic fatty liver disease (NAFLD).

NCT ID: NCT00885261 Completed - Clinical trials for Pain and Metabolic Syndrome

The Prevalence of Metabolic Syndrome in Patients Suffering From Chronic Pain

Start date: May 2009
Phase: N/A
Study type: Observational

Obesity is considered as the epidemic of the century. Central obesity is one of the metabolic syndrome's features. It has been proven that obesity can cause back pain and headaches; thus, there might be a link between chronic pain and the syndrome. The objective of this study is to assess the prevalence of metabolic syndrome in patients suffering from chronic pain.

NCT ID: NCT00874952 Completed - Metabolic Syndrome Clinical Trials

Regional Observation of the Metabolic Syndrome

ORSA
Start date: March 2009
Phase: N/A
Study type: Observational

The aim of the study, is to assess the prevalence of metabolic syndrome in Italy on a regional basis, defined according to National Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATPIII) guidelines criteria.

NCT ID: NCT00873964 Active, not recruiting - Clinical trials for Metabolic Syndrome in the Elderly

Metabolic Syndrome in an Elderly Population is More Linked to Insulin Resistance Than to Obesity

Start date: March 2009
Phase: N/A
Study type: Observational

In the United States cardiovascular disease (CVD) accounts for 1 in every 2.8 deaths and is the leading cause of death among men and women 65 years or older (1). Studies have shown that the risk for cardiovascular disease is higher in individuals with the Metabolic Syndrome (2). Metabolic Syndrome (MBS) is defined by the Adult Treatment Panel III (ATP III) guidelines as a group of risk factors that includes 3 or more of the following: abdominal obesity, hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol, high blood pressure, and high fasting glucose (3). These factors place individuals at increased risk for the development of both cardiovascular disease (CVD) and diabetes mellitus (3). It is commonly held that insulin resistance is the driving force for the development of the MBS. Although there is a significant increase in incidence of MBS in the elderly, there are few studies that specifically examined MBS in that population. The prevailing opinion is that the strikingly high prevalence of the MBS in the elderly is due to concurrent obesity - i.e., the population gains weight as it ages, and development of the MBS accompanies the weight gain. However, while it is true that becoming obese may decrease insulin sensitivity, it has also been demonstrated that not all obese individuals are insulin resistant. Some studies suggest that up to 40% of obese individuals demonstrate normal insulin sensitivity (4). In addition, it is notable that the rate of increasing MBS in the population exceeds that of the rate of increasing BMI, suggesting that, while BMI may be a modulating factor, another factor independent of obesity also contributes to the development of MBS in the elderly. It is the investigators hypothesize that the MBS in the obese elderly population is primarily linked to insulin resistance and not to obesity per se. The investigators propose to test this hypothesis by assessing MBS and insulin resistance in a population of obese elderly men and women and then determining whether or not the MBS tracks with insulin resistance.